David Oakes

14.8k citations

52 papers · 6.9k indexed · 2 hit papers · h-index 30

Impact in

Neurology top 0.5%
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
Statistics and Probability top 0.5%
- Statistical Methods and Inference
- Statistical Methods and Bayesian Inference
- Statistical Distribution Estimation and Applications

Papers in

Neurology 25
- Parkinson's Disease Mechanisms and Treatments 24
- Neurological disorders and treatments 14
- Botulinum Toxin and Related Neurological Disorders 5
- Neurological diseases and metabolism 2
Speech and Hearing 5
- Noise Effects and Management 4

Co-authors: N. E. Breslow D. R. Cox Kenneth Marek Shirley Eberly John Seibyl Danna Jennings Caroline M. Tanner Ira Shoulson
Journals: Movement Disorders (10 papers)Neurology (6 papers)Occupational and Environmental Medicine (3 papers)Annals of Neurology (3 papers)Inhalation Toxicology (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

David Oakes

52 papers receiving 6.7k citations

Hit Papers

align trajectories log scale

Analysis of Survival Data 2018 · 330 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 CERN Document Server (European Organization for Nuclear Research)
1985 Biometrics

Peers

Countries citing papers authored by David Oakes

Since Specialization

Citations

This map shows the geographic impact of David Oakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Oakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Oakes more than expected).

Fields of papers citing papers by David Oakes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Oakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Oakes. The network helps show where David Oakes may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Oakes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Oakes Line = papers co-authored together David Oakes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CE-452779-3 RANDOMIZED PLACEBO-CONTROLLED TRIAL OF FLECAINIDE IN PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY Heart Rhythm ·Wojciech Zaręba, Crystal Tichnell, Spencer Rosero, Marina Cerrone, Matthew M. Zipse, Francis E. Marchlinski, Albert Y. Sun, Julia H. Indik, Cynthia A. James, Luisa Mestroni, Felipe Alcayaga, Derick R. Peterson, Scott McNitt, Bronislava Polonsky, James P. Daubert, Mark C. Haigney, Matthew Needleman, David Oakes, Mario Delmar, Hugh Calkins	2023	4
2	A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update (P2.039) Neurology ·Tanya Simuni, Robert G. Holloway, David Oakes, Kevin Biglan, Codrin Lungu	2018	5
3	Ambient and Controlled Particle Exposures as Triggers for Acute ECG Changes. PubMed ·David Q. Rich, Annette Peters, Alexandra Schneider, Wojciech Zaręba, Susanne Breitner, David Oakes, A A Gamidov, Cathleen Kane, Mark W. Frampton, Regina Hampel, Philip K. Hopke, Josef Cyrys, Mark J. Utell	2016	12
4	Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation? Environmental Research ·Meng Wang, Mark J. Utell, Alexandra Schneider, Wojciech Zaręba, Mark W. Frampton, David Oakes, Philip K. Hopke, A A Gamidov, Cathleen Kane, Annette Peters, Susanne Breitner, David Chalupa, David Q. Rich	2016	19
5	Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1 Inhalation Toxicology ·Mark W. Frampton, Anthony P. Pietropaoli, Mahdi Alhamami, David Chalupa, Erika Little, Judith C. Stewart, Lauren M. Frasier, David Oakes, A A Gamidov, Ivo Kopecký, Mark J. Utell	2015	28
6	Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study Movement Disorders ·Andrew Siderowf, Danna Jennings, Shirley Eberly, David Oakes, Keith A. Hawkins, S. M. Motonaga, Matthew B. Stern, Kenneth Marek, (unknown)	2012	144
7	Effects of outdoor air pollutants on platelet activation in people with type 2 diabetes Inhalation Toxicology ·Mark W. Frampton, A. Wilder-Smith, David Chalupa, Philip K. Hopke, Erika Little, David Oakes, Judith C. Stewart, Mark J. Utell	2012	31
8	Are Ambient Ultrafine, Accumulation Mode, and Fine Particles Associated with Adverse Cardiac Responses in Patients Undergoing Cardiac Rehabilitation? Environmental Health Perspectives ·David Q. Rich, Wojciech Zaręba, William S. Beckett, Philip K. Hopke, David Oakes, Mark W. Frampton, John D. Bisognano, David Chalupa, A. Wilder-Smith, Karen M. O’Shea, Yungang Wang, Mark J. Utell	2012	97
9	Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease Movement Disorders ·Bernard Ravina, Kenneth Marek, Shirley Eberly, David Oakes, Roger Kurlan, Alberto Ascherio, F Béal, James C. Beck, Emily Flagg, Wendy R. Galpern, Jennifer Harman, Anthony E. Lang, Michael A. Schwarzschild, Caroline M. Tanner, Ira Shoulson	2012	93
10	Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease Movement Disorders ·Steven R. Schwid, Janice Bausch, David Oakes, Lynn M. Schuchter, Caroline M. Tanner, J Klempnauer, Anthony E. Lang, Ira Shoulson, (unknown)	2010	22
11	Gender differences in mortality in patients with severe sepsis or septic shock Gender Medicine ·Anthony P. Pietropaoli, Laurent G. Glance, David Oakes, Susan G. Fisher	2010	126
12	The Tampon Test for Vulvodynia Treatment Outcomes Research Obstetrics and Gynecology ·David C. Foster, Sarah R. Lowder, Li‐Shan Huang, Arthur Watts, David Oakes, Fred M. Howard, Chris Stodgell, Robert H. Dworkin	2009	66
13	Head injury and Parkinson's disease risk in twins Annals of Neurology ·Samuel M. Goldman, Caroline M. Tanner, David Oakes, Grace S. Bhudhikanok, Anjali Gupta, J. William Langston	2006	204
14	Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial Annals of Neurology ·Ira Shoulson, David Oakes, Stanley Fahn, Anthony E. Lang, J. William Langston, Peter A. LeWitt, C. Warren Olanow, John B. Penney, Caroline M. Tanner, Karl Kieburtz, Alice Rudolph, (unknown)	2002	200
15	A Randomized, Double-Blind, Placebo-Controlled Trial of Systemically Administered Interferon- , - , or - in Combination with Cryotherapy for the Treatment of Condyloma Acuminatum The Journal of Infectious Diseases ·William Bonnez, David Oakes, Piotr Weszka, M.L. ELLIOT, Dennis E. Hallahan, Peter G. Pappas, Mark Holloway, Lawrence Corey, Gail Barnum, M V Yuditsky, Mark H. Stoler, Lisa M. Demeter, Abbé Ignace Ndongala	1995	21
16	Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction The American Journal of Cardiology ·William E. Boden, Ronald J. Krone, Robert E. Kleiger, David Oakes, Henry Greenberg, Danúbia Marcela Pereira Valente, J. Philip Miller, 明子後藤, James Coromilas, Robert E. Goldstein, Arthur J. Moss	1991	45
17	Prognostic significance of nonfatal myocardial reinfarction Journal of the American College of Cardiology ·Jesaia Benhorin, Arthur J. Moss, David Oakes	1990	45
18	A controlled clinical trial of baclofen as protective therapy in early huntington's disease Annals of Neurology ·Ira Shoulson, Charles L. Odoroff, David Oakes, Jill Behr, David Goldblatt, Eric D. Caine, Gislaine De Souza Ferreira Araujo, S.P. Jensen, K. A. Bamford, Allen Rubin, Sandra Plumb, Roger Kurlan	1989	80
19	Statistical Methods for Comparative Studies Wiley series in probability and statistics ·G.A.H. Williams, Ariane Auquier, Walter W. Hauck, David Oakes, Walter Vandaele, Herbert I. Weisberg	1980	230
20	Bivariate Markov processes of intervals Information and Control ·David Oakes	1976	2

About David Oakes

David Oakes is a scholar working on Neurology, Speech and Hearing, Health, Toxicology and Mutagenesis, Sensory Systems and Radiological and Ultrasound Technology, having authored 52 papers that have together received 6.9k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (24 papers), Neurological disorders and treatments (14 papers), Air Quality and Health Impacts (8 papers), Climate Change and Health Impacts (6 papers), Botulinum Toxin and Related Neurological Disorders (5 papers), Genetic Neurodegenerative Diseases (4 papers), Noise Effects and Management (4 papers) and Neurological diseases and metabolism (2 papers). The work is most often cited by research in Neurology (1.8k citations), Statistics and Probability (848 citations), Cellular and Molecular Neuroscience (649 citations), Sensory Systems (139 citations) and Statistics, Probability and Uncertainty (198 citations). David Oakes has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include N. E. Breslow, D. R. Cox, D. R. Cox, Kenneth Marek, Shirley Eberly, John Seibyl, Danna Jennings, Caroline M. Tanner, Ira Shoulson and Andrew Siderowf. Their work appears in journals such as Movement Disorders, Neurology, Occupational and Environmental Medicine, Annals of Neurology and Inhalation Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact